Cargando…

Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients

PURPOSE: Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) offers a novel bariatric procedure with few comparative studies evaluating patient selection or perioperative outcomes. We aim to compare SADI-S to Roux-en-Y gastric bypass (RYGB). MATERIALS AND METHODS: The 2020 Metab...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoeff, Kevin, Mocanu, Valentin, Jogiat, Uzair, Forbes, Hayley, Switzer, Noah J., Birch, Daniel W., Karmali, Shahzeer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022408/
https://www.ncbi.nlm.nih.gov/pubmed/35445967
http://dx.doi.org/10.1007/s11695-022-06068-y
_version_ 1784690077785391104
author Verhoeff, Kevin
Mocanu, Valentin
Jogiat, Uzair
Forbes, Hayley
Switzer, Noah J.
Birch, Daniel W.
Karmali, Shahzeer
author_facet Verhoeff, Kevin
Mocanu, Valentin
Jogiat, Uzair
Forbes, Hayley
Switzer, Noah J.
Birch, Daniel W.
Karmali, Shahzeer
author_sort Verhoeff, Kevin
collection PubMed
description PURPOSE: Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) offers a novel bariatric procedure with few comparative studies evaluating patient selection or perioperative outcomes. We aim to compare SADI-S to Roux-en-Y gastric bypass (RYGB). MATERIALS AND METHODS: The 2020 Metabolic and Bariatric Accreditation and Quality Improvement Program (MBSAQIP) registry was analyzed, comparing SADI-S to RYGB. Bivariate analysis was performed to determine intergroup differences. Multivariable logistic regression determined factors associated with serious complications and mortality. RESULTS: We evaluated 47,375 patients, with 501 (1.1%) receiving SADI-S. Patients undergoing SADI-S had higher body mass index (51.4 ± 9.7 kg/m(2) SADI-S vs. 44.6 ± 7.9 kg/m(2) RYGB; p < 0.001), and more metabolic comorbidities including non-insulin dependent diabetes (21.7% SADI-S vs 19.0% RYGB; p = 0.011), insulin dependent diabetes (12.0% SADI-S vs. 8.6% RYGB; p = 0.011), and hypertension (54.9% SADI-S vs 47.6% RYGB; p < 0.001). Patients undergoing SADI-S experienced more anastomotic leaks (2.2% vs. 0.5%; p < 0.001), reoperations (5.0% vs 2.6%; p < 0.001), pneumonias (1.6% vs 0.5%; p < 0.001), had sepsis more frequently (1.4% vs 0.3%; p < 0.001), and required more unplanned reintubations (1.2% vs 0.3%; p = 0.004). SADI-S was independently associated with serious complications (OR 1.45, CI 1.09–1.95, p < 0.001) but was not a predictor of mortality (OR 3.29, p = 0.060). CONCLUSIONS: In comparison to RYGB, patients undergoing SADI-S were found to have more metabolic comorbidities. Compared to RYGB, SADI-S has worse perioperative outcomes and is independently associated with serious complications. It remains unclear whether this represents a learning curve or true findings and prospective studies analyzing the risk–benefit ratio following SADI-S are needed. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-9022408
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-90224082022-04-21 Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients Verhoeff, Kevin Mocanu, Valentin Jogiat, Uzair Forbes, Hayley Switzer, Noah J. Birch, Daniel W. Karmali, Shahzeer Obes Surg Original Contributions PURPOSE: Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) offers a novel bariatric procedure with few comparative studies evaluating patient selection or perioperative outcomes. We aim to compare SADI-S to Roux-en-Y gastric bypass (RYGB). MATERIALS AND METHODS: The 2020 Metabolic and Bariatric Accreditation and Quality Improvement Program (MBSAQIP) registry was analyzed, comparing SADI-S to RYGB. Bivariate analysis was performed to determine intergroup differences. Multivariable logistic regression determined factors associated with serious complications and mortality. RESULTS: We evaluated 47,375 patients, with 501 (1.1%) receiving SADI-S. Patients undergoing SADI-S had higher body mass index (51.4 ± 9.7 kg/m(2) SADI-S vs. 44.6 ± 7.9 kg/m(2) RYGB; p < 0.001), and more metabolic comorbidities including non-insulin dependent diabetes (21.7% SADI-S vs 19.0% RYGB; p = 0.011), insulin dependent diabetes (12.0% SADI-S vs. 8.6% RYGB; p = 0.011), and hypertension (54.9% SADI-S vs 47.6% RYGB; p < 0.001). Patients undergoing SADI-S experienced more anastomotic leaks (2.2% vs. 0.5%; p < 0.001), reoperations (5.0% vs 2.6%; p < 0.001), pneumonias (1.6% vs 0.5%; p < 0.001), had sepsis more frequently (1.4% vs 0.3%; p < 0.001), and required more unplanned reintubations (1.2% vs 0.3%; p = 0.004). SADI-S was independently associated with serious complications (OR 1.45, CI 1.09–1.95, p < 0.001) but was not a predictor of mortality (OR 3.29, p = 0.060). CONCLUSIONS: In comparison to RYGB, patients undergoing SADI-S were found to have more metabolic comorbidities. Compared to RYGB, SADI-S has worse perioperative outcomes and is independently associated with serious complications. It remains unclear whether this represents a learning curve or true findings and prospective studies analyzing the risk–benefit ratio following SADI-S are needed. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2022-04-21 2022 /pmc/articles/PMC9022408/ /pubmed/35445967 http://dx.doi.org/10.1007/s11695-022-06068-y Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Contributions
Verhoeff, Kevin
Mocanu, Valentin
Jogiat, Uzair
Forbes, Hayley
Switzer, Noah J.
Birch, Daniel W.
Karmali, Shahzeer
Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients
title Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients
title_full Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients
title_fullStr Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients
title_full_unstemmed Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients
title_short Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients
title_sort patient selection and 30-day outcomes of sadi-s compared to rygb: a retrospective cohort study of 47,375 patients
topic Original Contributions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022408/
https://www.ncbi.nlm.nih.gov/pubmed/35445967
http://dx.doi.org/10.1007/s11695-022-06068-y
work_keys_str_mv AT verhoeffkevin patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients
AT mocanuvalentin patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients
AT jogiatuzair patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients
AT forbeshayley patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients
AT switzernoahj patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients
AT birchdanielw patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients
AT karmalishahzeer patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients